DE69802828T2 - Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen - Google Patents

Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen

Info

Publication number
DE69802828T2
DE69802828T2 DE69802828T DE69802828T DE69802828T2 DE 69802828 T2 DE69802828 T2 DE 69802828T2 DE 69802828 T DE69802828 T DE 69802828T DE 69802828 T DE69802828 T DE 69802828T DE 69802828 T2 DE69802828 T2 DE 69802828T2
Authority
DE
Germany
Prior art keywords
substituted
aminotetraline
cytokin
flammability
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69802828T
Other languages
English (en)
Other versions
DE69802828D1 (de
Inventor
Piero Foresta
Vito Ruggiero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE69802828D1 publication Critical patent/DE69802828D1/de
Publication of DE69802828T2 publication Critical patent/DE69802828T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69802828T 1997-09-22 1998-09-18 Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen Expired - Fee Related DE69802828T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000569A IT1294932B1 (it) 1997-09-22 1997-09-22 Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
PCT/IT1998/000250 WO1999015160A2 (en) 1997-09-22 1998-09-18 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies

Publications (2)

Publication Number Publication Date
DE69802828D1 DE69802828D1 (de) 2002-01-17
DE69802828T2 true DE69802828T2 (de) 2002-07-18

Family

ID=11405258

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69802828T Expired - Fee Related DE69802828T2 (de) 1997-09-22 1998-09-18 Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen

Country Status (17)

Country Link
US (1) US6242497B1 (de)
EP (1) EP1017377B1 (de)
JP (1) JP2001517618A (de)
KR (1) KR20010030670A (de)
CN (1) CN1276721A (de)
AT (1) ATE209910T1 (de)
AU (1) AU735369B2 (de)
BR (1) BR9812489A (de)
CA (1) CA2303918A1 (de)
DE (1) DE69802828T2 (de)
DK (1) DK1017377T3 (de)
ES (1) ES2167942T3 (de)
IT (1) IT1294932B1 (de)
MX (1) MXPA00002774A (de)
NZ (1) NZ503391A (de)
PT (1) PT1017377E (de)
WO (1) WO1999015160A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1294931B1 (it) * 1997-09-22 1999-04-23 Sigma Tau Ind Farmaceuti Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella
CN102655860B (zh) 2009-10-16 2013-11-06 艾皮奥梅医药公司 呕吐的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241988B (it) * 1990-06-15 1994-02-02 Sigma Tau Ind Farmaceuti 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono
IT1278045B1 (it) * 1995-03-09 1997-11-17 Sigma Tau Ind Farmaceuti Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di

Also Published As

Publication number Publication date
WO1999015160A2 (en) 1999-04-01
NZ503391A (en) 2001-06-29
DK1017377T3 (da) 2002-03-04
EP1017377B1 (de) 2001-12-05
CA2303918A1 (en) 1999-04-01
CN1276721A (zh) 2000-12-13
PT1017377E (pt) 2002-04-29
EP1017377A2 (de) 2000-07-12
AU735369B2 (en) 2001-07-05
AU9366198A (en) 1999-04-12
JP2001517618A (ja) 2001-10-09
MXPA00002774A (es) 2002-10-31
IT1294932B1 (it) 1999-04-23
ES2167942T3 (es) 2002-05-16
WO1999015160A3 (en) 1999-05-20
BR9812489A (pt) 2000-09-26
DE69802828D1 (de) 2002-01-17
ITRM970569A1 (it) 1999-03-22
ATE209910T1 (de) 2001-12-15
KR20010030670A (ko) 2001-04-16
US6242497B1 (en) 2001-06-05

Similar Documents

Publication Publication Date Title
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
EA199800667A1 (ru) Новые фенантридины
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE59310137D1 (de) Verwendung von substituierten Benzimidazolen zur Bekämpfung parasitärer Protozoen
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
MX9302011A (es) Derivados de indol.
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
TR199700416A2 (xx) Fluorinlenmi� vitamin D3 analoglar�.
DE3778158D1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
EA199900174A1 (ru) Способ лечения биполярного расстройства

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee